Evidence map›Paper›PMID 25505671›Full record

ArticleInternational journal of bipolar disorders2013

Aripiprazole as augmentation therapy in bipolar patients with current minor or subsyndromal mood symptoms.

Isaac Schweitzer, Jerome Sarris, Virginia Tuckwell, Kay Maguire, Deidre Smith, Chee Ng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of bipolar disorders, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Isaac SchweitzerDepartment of Psychiatry, University of Melbourne, The Melbourne Clinic, 130 Church St, Richmond, 3121 Australia.
Jerome SarrisDepartment of Psychiatry, University of Melbourne, The Melbourne Clinic, 130 Church St, Richmond, 3121 Australia ; Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, 3122 Australia.
Virginia TuckwellDepartment of Psychiatry, University of Melbourne, The Melbourne Clinic, 130 Church St, Richmond, 3121 Australia.
Kay MaguireDepartment of Psychiatry, University of Melbourne, The Melbourne Clinic, 130 Church St, Richmond, 3121 Australia.
Deidre SmithDepartment of Psychiatry, University of Melbourne, The Melbourne Clinic, 130 Church St, Richmond, 3121 Australia.
Chee NgDepartment of Psychiatry, University of Melbourne, The Melbourne Clinic, 130 Church St, Richmond, 3121 Australia.
University of Melbourne · AUMelbourne Clinic · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aims to evaluate the effectiveness of aripiprazole augmentation of maintenance treatment for bipolar disorder in patients with minor or subsyndromal mood episodes while on a stable dose of a mood stabiliser and/or antidepressant.

methodsAll subjects had a diagnosis of bipolar I or II disorder (Diagnostic and Statistical Manual of Mental Disorders-4th Edition, Text Revision). Open-label aripiprazole was given over 8 weeks initially. The starting dose was 5 to 15 mg/day with a mean final dose of 11.5 mg (±4.6). Patients were assessed at weeks 0, 2, 4 and 8 with the Montgomery-Asberg Depression Rating Scale (MADRS), Young Mania Rating Scale (YMRS) and Clinical Global Impression of Severity (CGI-S). RESULTS AND DISCUSSION: Seventeen of 20 (85%) patients completed week 4, while 14 (70%) patients completed 8 weeks. For intention-to-treat data, there was a significant decrease in MADRS scores over the course of treatment, with a reduction of 6.40 points at endpoint (p < 0.0005). Improvement from baseline was significant at week 2 and remained through to week 8. Similarly, CGI-S scores significantly decreased over the course of study, but not YMRS scores. Aripiprazole was shown to be a modestly effective augmentation therapy for depressive symptoms in bipolar I and II in this small open-label study.

Indexed as

AdjunctiveAripiprazoleAtypical antipsychoticsAugmentation therapyBipolar depressionBipolar disorder

Identifiers

PMID25505671
PMCPMC4230314
OpenAlexW2115315866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.